Advertisement
Cellectricon and AstraZeneca formed and announced a collaboration in May2006 aiming to find a solution to major bottlenecks in ligand gated ionchannel screening. The results from this collaboration have successfullydemonstrated the unique performance of Cellectricon's cell-based microfluidicscreening platform. It has clearly demonstrated the opportunity to introducethe fully automated Dynaflow(R)HT System with unmatched level of stabilityand throughput while still delivering unique measurement data quality. TheDynaflow(R)HT System will be launched and commercially available in 2009.
Advertisement
"Collaborating with AstraZeneca has been most rewarding," says JonasOhlsson, CEO at Cellectricon. "Driven by solving bottlenecks in drugdiscovery, Cellectricon's strategy is to bring state-of-the-art products fordrug discovery and research to the market through world-class customercollaborations."
"This collaboration aims to accelerate our efforts in ion channel drugdiscovery and has been very fruitful to date. We look forward to working withthe Dynaflow@HT Systems and see the impact of their throughput and costeffectiveness," says Dr. Jan-Erik Nystrom, VP Local Discovery Research AreaCNS & Pain Control, Sodertalje, Sweden.
"The strength of this platform is that it is based on many years ofcutting-edge academic and industrial research in ion channel drug discovery.I am happy to see us taking a new step together with a leading partner inadvancing it further," says Dr. Jon Sinclair, VP Research & Development atCellectricon.
About Cellectricon
Cellectricon AB (http://www.cellectricon.com), a Swedish biotech company,successfully provides groundbreaking products to the pharmaceutical andbiotechnology industries. The company utilizes state-of-the-art interfaces tobiological systems by employing novel microfluidic technologies. This enablescompletely new types of assays and devices with superior performancecharacteristics and robustness. Cellectricon's products address criticalbottlenecks in the drug discovery process and have been adopted bytop-reference customers, including nine of the top ten pharmaceuticalcompanies. In 2007 the company increased its annual revenue by almost 50%. In2008-2009 the company will launch two pioneering large-scale screeningplatforms developed in close collaboration with leaders in the pharmaceuticalindustry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HTSystem enables high throughput RNAi screening and the Dynaflow(R)HT Systemgreatly advances ion channel drug discovery.
SOURCE Cellectricon AB
